EGFR and non-small cell lung carcinoma: Specifically, our preliminary analysis in a small sample of 34 NSCLC patients showed that EGFR wild‐type patients were more likely to experience irAEs than EGFR driver mutation‐positive counterparts (OR: 14.44, p = 0.019).